Sofinnova Investments Inc. Buys Shares of 46,201 Masimo Corporation $MASI

Sofinnova Investments Inc. bought a new stake in Masimo Corporation (NASDAQ:MASI) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 46,201 shares of the medical equipment provider’s stock, valued at approximately $6,009,000.

A number of other large investors have also recently modified their holdings of MASI. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Masimo by 10.7% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 7,523 shares of the medical equipment provider’s stock valued at $978,000 after acquiring an additional 730 shares during the last quarter. Verition Fund Management LLC boosted its position in shares of Masimo by 463.9% during the 4th quarter. Verition Fund Management LLC now owns 53,020 shares of the medical equipment provider’s stock valued at $6,896,000 after purchasing an additional 43,617 shares in the last quarter. Mariner LLC acquired a new stake in Masimo during the fourth quarter worth approximately $2,789,000. Aigen Investment Management LP acquired a new stake in Masimo during the fourth quarter worth approximately $262,000. Finally, FORA Capital LLC grew its stake in Masimo by 42.8% during the fourth quarter. FORA Capital LLC now owns 5,174 shares of the medical equipment provider’s stock worth $673,000 after purchasing an additional 1,552 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Price Performance

MASI opened at $179.95 on Tuesday. The stock has a market cap of $9.42 billion, a PE ratio of -17.07, a P/E/G ratio of 1.82 and a beta of 1.11. The company has a quick ratio of 1.45, a current ratio of 2.68 and a debt-to-equity ratio of 0.56. Masimo Corporation has a 52 week low of $125.94 and a 52 week high of $179.99. The business’s fifty day simple moving average is $178.72 and its 200 day simple moving average is $160.89.

Wall Street Analyst Weigh In

A number of analysts recently commented on MASI shares. Piper Sandler lowered Masimo from an “overweight” rating to a “hold” rating and set a $180.00 target price for the company. in a research report on Tuesday, February 17th. Wolfe Research downgraded Masimo from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 19th. Raymond James Financial downgraded Masimo from an “outperform” rating to a “market perform” rating in a research note on Friday, March 27th. Stifel Nicolaus set a $180.00 price objective on Masimo in a research note on Tuesday, February 17th. Finally, BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Masimo presently has an average rating of “Hold” and a consensus price target of $180.40.

Masimo Profile

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.